Cargando…
What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614101/ https://www.ncbi.nlm.nih.gov/pubmed/31309097 http://dx.doi.org/10.5045/br.2019.54.2.153 |
| _version_ | 1783433123192635392 |
|---|---|
| author | Sekiguchi, Naohiro Hamano, Airi Kitagawa, Tomoko Ito, Kenichi Hirano, Kazuhiko Yamada, Kazuaki |
| author_facet | Sekiguchi, Naohiro Hamano, Airi Kitagawa, Tomoko Ito, Kenichi Hirano, Kazuhiko Yamada, Kazuaki |
| author_sort | Sekiguchi, Naohiro |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6614101 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-66141012019-07-15 What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness Sekiguchi, Naohiro Hamano, Airi Kitagawa, Tomoko Ito, Kenichi Hirano, Kazuhiko Yamada, Kazuaki Blood Res Letters to the Editor Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019-06 2019-06-25 /pmc/articles/PMC6614101/ /pubmed/31309097 http://dx.doi.org/10.5045/br.2019.54.2.153 Text en © 2019 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters to the Editor Sekiguchi, Naohiro Hamano, Airi Kitagawa, Tomoko Ito, Kenichi Hirano, Kazuhiko Yamada, Kazuaki What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness |
| title | What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness |
| title_full | What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness |
| title_fullStr | What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness |
| title_full_unstemmed | What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness |
| title_short | What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness |
| title_sort | what is the most appropriate regimen for untreated waldenström macroglobulinemia? - an updated analysis of rituximab and half-dose chop therapy and cost effectiveness |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614101/ https://www.ncbi.nlm.nih.gov/pubmed/31309097 http://dx.doi.org/10.5045/br.2019.54.2.153 |
| work_keys_str_mv | AT sekiguchinaohiro whatisthemostappropriateregimenforuntreatedwaldenstrommacroglobulinemiaanupdatedanalysisofrituximabandhalfdosechoptherapyandcosteffectiveness AT hamanoairi whatisthemostappropriateregimenforuntreatedwaldenstrommacroglobulinemiaanupdatedanalysisofrituximabandhalfdosechoptherapyandcosteffectiveness AT kitagawatomoko whatisthemostappropriateregimenforuntreatedwaldenstrommacroglobulinemiaanupdatedanalysisofrituximabandhalfdosechoptherapyandcosteffectiveness AT itokenichi whatisthemostappropriateregimenforuntreatedwaldenstrommacroglobulinemiaanupdatedanalysisofrituximabandhalfdosechoptherapyandcosteffectiveness AT hiranokazuhiko whatisthemostappropriateregimenforuntreatedwaldenstrommacroglobulinemiaanupdatedanalysisofrituximabandhalfdosechoptherapyandcosteffectiveness AT yamadakazuaki whatisthemostappropriateregimenforuntreatedwaldenstrommacroglobulinemiaanupdatedanalysisofrituximabandhalfdosechoptherapyandcosteffectiveness |